Reductions in posttraumatic stress disorder re-experiencing frequency from repetitive transcranial magnetic stimulation combined with Cognitive Processing Therapy.

Int Rev PsychiatryJul 5, 2026 (epub)
Clinical ResearchPsychiatry

Jordan Petry, Noureen Hoq, Likhita Kapadam et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) combined with Cognitive Processing Therapy (CPT) on PTSD symptoms in post-9/11 military veterans. The study found that rTMS + CPT significantly reduced the frequency of re-experiencing symptoms compared to sham rTMS + CPT, with sustained effects observed from session 9 through 6 months post-treatment.

Key findings

  • rTMS + CPT led to significantly greater reductions in re-experiencing frequency compared to sham + CPT.
  • The significant treatment effect was sustained from session 9 through the 6-month follow-up.
  • No significant effects were observed for other PTSD symptom clusters.

Why it matters

Understanding the specific effects of rTMS on PTSD symptom clusters can help clinicians tailor treatments for better patient outcomes, particularly in addressing re-experiencing symptoms that significantly impact quality of life.

Source

PubMed · PMID 42402165

Published in Int Rev Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.